A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- MD Verastem
Verastem, Inc.
Study Director - Rachel Grisham, MD
GOG Foundation
Principal Investigator - Susana Banerjee, MBBS,MA,PhD
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
47 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uz Gent Medische Oncologie
Ghent, Belgium
- Uz Leuven
Leuven, Belgium
- Chu de Liege
Liège, Belgium
- Centre de Recherche Di Centre Hospitalier de I'Universite de Montreal
Montreal, Canada
- Princess Margaret Cancer Centre
Toronto, Canada
- Hopital Jean Minjoz
Besançon, France
- Centre Leon Berard
Lyon, France
- Icm - Val D'Aurelle
Montpellier, France
- Institut Curie
Paris, France
- Insituto Europeo Di Oncologia I.R.C.C.S
Milan, Italy
- U.O.C. Oncologia 2, Istituto Oncologico Veneto I.R.C.C.S.
Padova, Italy
- Hospital Universitario Vall D'Hebron
Barcelona, Spain
- Hospital Universitario Reina Sofia
Córdoba, Spain
- Hospital Universitario Ramon Y Cajal
Madrid, Spain
- Hospital Clínico Universitario de Valencia
Valencia, Spain
- Western General Hospital
Edinburgh, United Kingdom
- Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
- Uclh Cancer Clinical Trials Unit
London, United Kingdom
- the Christie Nhs Foundation Trust
Manchester, United Kingdom
- Royal Marsden Hospital
Sutton, United Kingdom
- Arizona Oncology Associates Pc Hal
Scottsdale, Arizona, United States
- Sansum Clinic
Santa Barbara, California, United States
- Yale School of Medicine
New Haven, Connecticut, United States
- Advent Health
Orlando, Florida, United States
- H. Lee Moffitt Cancer Center and Research Institute - Center for Women'S Oncology
Tampa, Florida, United States
- University of Chicago
Chicago, Illinois, United States
- Maryland Oncology and Hematology, P.A.
Glenn Dale, Maryland, United States
- Minnesota Oncology Hematology Pa
Minneapolis, Minnesota, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
- University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Cleveland Clinic Women'S Health Institute
Cleveland, Ohio, United States
- the Ohio State University Wexner Medical Center
Columbus, Ohio, United States
- University of Oklahoma Medical Center
Oklahoma City, Oklahoma, United States
- Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, United States
- Northwest Cancer Specialists
Portland, Oregon, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- Texas Oncology Austin Central
Austin, Texas, United States
- Texas Oncology- Dallas Presbyterian Hospital
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Dec 2020
- Primary completion
- 15 Nov 2024
- Completion
- 31 Dec 2026
- Last update posted
- 29 Jan 2025
- Registered enrollment
- 225
- Registry id
- NCT04625270
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.